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carboplatin (instead of cisplatin) in patients with metastatic/locally
advanced breast cancer (infusional ECarboF): a very active and well-
tolerated outpatient regimen
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Summary Infusional 5-fluorouracil (F) with cisplatin (C) and epirubicin (E), so-called infusional ECF, is a
highly active new schedule against locally advanced or metastatic breast cancer. Cisplatin, however, is a major
contributor to toxicity and usually requires inpatient treatment. In an attempt to overcome this, we have
investigated the effect of substituting carboplatin for cisplatin in our original infusional ECF regimen. Fifty-
two patients with metastatic (n = 36) or locally advanced/inflammatory (n = 16) breast cancer were treated with
5-fluorouracil 200 mg m2 day 1 via a Hickman line using an ambulatory pump for 6 months, with epirubicin
50 mg m-2 intravenously (i.v.) and carboplatin AUC5 i.v. every 4 weeks, for six courses (infusional ECarboF).
The overall response rate (complete plus partial) was 81% (95% CI 67%-90%), with a complete response rate
of 17% (95% CI 6-33%) in patients with metastatic disease and 56% (95% CI 30-80%) in patients with
locally advanced disease. Median response duration and survival for metastatic disease was 8 and 14 months
respectively, and two patients with locally advanced disease have relapsed. These results are very similar to
those previously achieved with infusional ECF. Severe grade 3/4 toxicity was low. Infusional ECarboF is a
highly active, well-tolerated, outpatient regimen effective against advanced/metastatic breast cancer and now
warrants evaluation against conventional chemotherapy in high-risk early breast cancer.
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Continuous infusional 5-fluorouracil (5-FU) for up to 6
months, with 3-weekly bolus cisplatin and epirubicin (so-
called infusional ECF) has been shown to be a highly active
new schedule in the treatment of locally advanced or
metastatic breast cancer with an overall response rate of
84% (Jones et al., 1994). Subsequently, the same regimen
achieved an overall response rate of 98% and a complete
remission rate of 66% as primary/neoadjuvant chemotherapy
for large early breast cancer (Smith et al., 1995). The schedule
has also shown high activity in the treatment of advanced
gastric carcinoma with a response rate of 71% (Findlay et al.,
1994).
The underlying rationale for this schedule is as follows:
Phase I studies have demonstrated that 5-FU can be
administered by protracted continuous infusion at a dose of
300 mg m-2 day-' without interruption for up to 60 days or
up to 36 g cumulative dose (Lokich et al., 1981); response
rates of up to 53% have been reported in patients with
metastatic breast cancer extensively pretreated with che-
motherapy (Huan et al., 1989). This represents a more than
3-fold increase in response compared with conventional
studies. In an overview of six phase II studies involving 182
patients with refractory breast cancer, most of whom were
pretreated with bolus 5-FU, an average response rate of 29%
(range 17-53%) has been reported (Hansen, 1991). As
originally suggested in the phase I study by Lokich and
subsequently confirmed by phase II studies, myelosuppres-
sion, an important toxic effect occurring with bolus
administration, is rarely reported with infusional 5-FU and
the dose-limiting toxicities are stomatitis, diarrhoea and
plantar-palmar erythema (Lokich et al., 1981; Hansen et
al., 1987; Huan et al., 1989).
Anthracyclines, including epirubicin, are still the most
active drugs used as single agents in advanced breast cancer
(Henderson, 1987). Cisplatin is an active agent as first-line
treatment for advanced breast cancer with an overall
response rate of 50% (33 out of 66 patients) in three small
studies (Kolaric and Roth, 1983; Mechl, 1988; Sledge et al.,
1988). Furthermore, clinical studies have reported a response
rate of 50-53% in patients with advanced breast cancer
treated wtih 5-FU administered by continuous infusion with
cisplatin (Fernandez-Hidalgo et al., 1989; Bitran et al.,
1990).
There are, however, disadvantages with cisplatin. Even
with modern antiemetics it is associated with significant
incidence of severe nausea and vomiting and is also
associated with neurotoxicity and nephrotoxicity. To prevent
this last problem patients require an overnight or extended
day-long admission for intravenous hydration.
Carboplatin has established advantages over cisplatin in
having a reduced risk of serious emesis, nephrotoxicity or
neurotoxicity (Calvert et al., 1982). In addition, it can be
given on a simple outpatient basis as a 1 h infusion. We
found that in previously untreated patients with metastatic
breast cancer, the carboplatin response rate was 33% (9 out
of 27 patients) (O'Brien et al., 1993), and others have
reported similar findings (Carmo Pereira et al., 1990; Kolaric
and Vukas, 1991; Martin et al., 1992). For these reasons we
have investigated the substitution of carboplatin to cisplatin
in our original infusional ECF schedule to try to devise a
simpler and more 'user friendly' infusional schedule for the
treatment of breast cancer. We report here the results of our
phase II study.
Patients and methods
Patients
Patients with cytologically or histologically confirmed
metastatic or locally advanced inoperable breast cancer were
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eligible for the study. The criteria for locally advanced breast
cancer were those reported by Haagensen and Stout (1943).
Inflammatory breast cancer was defined as a T4 lesion with
diffuse brawny induration of the breast with an erysipeloid
edge (Beahrs et al., 1992). Eligibility criteria included World
Health Organization (WHO) performance status 0-2;
adequate renal function (EDTA clearance >60 ml min-1);
adequate hepatic function (normal bilirubin< 17 jlimol 11)
and hepatic enzymes not elevated more than twice the normal
range; adequate bone marrow reserve (WBC count>3.0 x 109
1-', platelet count> 100 x 109 1-); at least one site of disease
that was measurable bidimensionally; and the ability to
manage an indwelling intravenous (i.v.) catheter. Patients
with cerebral metastases were eligible for inclusion provided
there was no major neurological deficit.
Patients with metastatic disease were only eligible provided
they had received no more than one prior chemotherapy
regimen for metastatic disease. Patients with locally advanced
inoperable breast cancer and inflammatory breast cancer
were eligible provided they had received no previous therapy.
The protocol was approved by the Royal Marsden
Hospital Ethics Committee and all patients gave written
informed consent.
Treatment
Patients were admitted for initial assessment, insertion of a
double-lumen Hickman line (Quinton, Kimal Scientific,
Uxbridge, UK) into the subclavian vein under sedation with
diazepam and local anaesthetic, and subsequent instruction
by senior nursing staff on the care of the line and technique
for changing the chemotherapy reservoir. Patients were
started on prophylactic low-dose warfarin 1 mg orally daily,
as this has been shown to decrease the risk of thrombosis
associated with an indwelling line (Bern et al., 1990). One
lumen of the Hickman line was used for infusional 5-FU,
which was made up in bags in the pharmacy and
administered using an Infumed 300 infusion pump
(Neurotechnics, Oxon, UK), allowing continuous ambula-
tory infusion for 7 days. Patients replaced the 5-FU
reservoirs at home. The other lumen was used for
epirubicin, carboplatin and other i.v. drugs or fluids.
The chemotherapy regimen was given in an outpatient
setting as follows: 5-FU 200 mg m-2 every 24 h by
continuous i.v. infusion for 6 months; epirubicin 50 mg m-2
by i.v. bolus given with carboplatin AUC5 in a 1 h infusion
of 500 ml of 5% dextrose every 4 weeks for six courses. The
total dose of carboplatin was calculated according to renal
function based on the area under the concentration-time
curve (AUC) as follows:
AUC (GFR +25) =total dose
where GFR is the glomerular filtration rate calculated by
EDTA clearance and an AUC of 5 (Calvert et al., 1989). The
5-FU infusion was started 4 h before the first course of
carboplatin because of the theoretical modulation of
carboplatin by 5-FU by analogy with cisplatin. The regimen
was designated infusional ECarboF.
Patients were offered scalp cooling with epirubicin to
decrease the risk of alopecia. Patients received prophylactic
antiemetics with dexamethasone 8 mg i.v., ondansetron 8 mg
i.v. and lorazepam 1-2 mg i.v. immediately before carbo-
platin and epirubicin, followed by dexamethasone 4 mg
orally three times daily and metoclopramide 10-20 mg
orally four times daily for 3 days after chemotherapy. All
patients received prophylactic mouth care using antiseptic
mouthwash and nystatin four times per day to decrease the
risk of mucositis and/or oral fungal infection.
Chemotherapy was continued for 6 months in those
patients who responded to treatment, provided there was
no excessive toxicity. On completion of treatment, warfarin
was discontinued and the Hickman line was removed under
local anaesthetic. Patients were restaged and monitored at 3
month intervals. Patients with metastatic disease received no
further treatment until relapse. Patients with locally
advanced/inflammatory disease received radiotherapy
(60 Gy in 25 fractions over 5 weeks) to the breast and
regional nodal areas, and tamoxifen 20 mg day-' orally for 2
years.
Dose modifications
Myelosuppression If the WBC count was less than 3.0 x 109
1-l and/or platelet count less than 100 x 1091l-, 5-FU was
continued but carboplatin and epirubicin were delayed for 1
week. If the blood count had recovered, treatment was then
administered at full dose. If the blood count had not
recovered, then treatment was delayed by 2 weeks and the
doses of both epirubicin and 5-FU were reduced by 25% and
the dose of carboplatin reduced from AUC5 to AUC4. If
there was a longer than 2 week delay, the doses of both
epirubicin and 5-FU were reduced by 50% and the dose of
carboplatin reduced to AUC3.
Patients' GFR was measured by chromium-51-labelled
EDTA clearance before the start of treatment and then
before the fourth course. The carboplatin dose was
recalculated before the fourth course on the basis of the
measured GFR.
Plantar-palmar syndrome Continuous toxicity with plan-
tar-palmar erythema is observed with infusional 5-FU. For
mild to moderate plantar-palmar erythema (dryness and
erythema with pain), patients continued 5-FU and were
prescribed pyridoxine (50 mg orally three times per day)
throughout treatment. For severe plantar-palmar erythema
(severe erythema with blistering and desquamation), pyridox-
ine was started and 5-FU was interrupted for 1 week until
healing had occurred. 5-FU was then restarted at a 25% dose
reduction, and pyridoxine was continued throughout treat-
ment.
Diarrhoea For WHO grade 1 or 2 diarrhoea, antidiarrhoeal
agents were prescribed, but for persistent diarrhoea 5-FU was
discontinued for 1 week and restarted at a 25% dose
reduction.
Mucositis In patients with grade 3 or 4 mucositis, infusional
5-FU was stopped for 1 week and then restarted at a 25%
dose reduction. Epirubicin was also subsequently given at a
25% dose reduction.
Assessment of response and toxicity
Patients were examined clinically before treatment: full blood
count, serum biochemistry, chest radiograph and measurement
of EDTA clearance to assess renal function. Patients with
metastatic disease had appropriate clinical and radiological
examination according to the site ofdisease, and bidimension-
allymeasurableandassessable lesions weremonitored. Patients
with locally advanced carcinoma were assessed clinically, as
well as by mammography and ultrasound.
Patients had a clinical examination and full blood count,
and a biochemistry before each cycle (28 days). Response was
assessed according to standard International Union Against
Cancer criteria (Hayward et al., 1977) after every two cycles
and on completion of treatment. Patients were then
monitored at 3 month intervals. Toxicity was assessed
according to WHO criteria after each cycle of chemotherapy
(WHO, 1979). Patients who received at least two cycles of
chemotherapy were assessable for response, and all patients
were assessable for toxicity. The response duration was
defined as the time elapsed between the start of treatment
with carboplatin and the date of progressive disease or last
follow-up evaluation.
Statistical considerations
This was an open-ended phase II study. The planned number
of patients was 50 to determine a predicted response rate of
75% to within+ 10%.ECarboF in breast cancer
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The x2 test and Mann-Whitney test for trend were used to
assess differences in toxicity between patients with metastatic
and locally advanced disease. Survival analysis and duration
of response were generated using the Kaplan-Meier life table
method (Kaplan and Meier, 1958).
Results
Patient characteristics
Between November 1992 and October 1994, 52 eligible
patients under the care of the Breast Unit at the Royal
Marsden Hospital, London and Sutton, were entered
sequentially into this study. The median age was 48 years
(range 33-62 years). Twenty-six patients were premenopau-
sal and 26 were peri- or post-menopausal. Thirty-six patients
had metastatic breast cancer and 16 had locally advanced or
inflammatory breast cancer (without overt metastases).
Fourteen patients with metastatic disease had received
previous chemotherapy. Eleven of these had received
adjuvant chemotherapy for early-stage breast cancer 0-80
months before they entered the study: cyclophosphamide,
methotrexate, 5-fluorouracil (CMF) in eight patients;
mitoxantrone, mitomycin (MM) in one patient; and
neoadjuvant CMF in two patients (one of these progressed
under neoadjuvant CMF and was entered in the ECarboF
study). Four patients had received one chemotherapy regimen
for metastatic disease between 0 and 13 months before
ECarboF: CMF in one, MM in one, phase II topotecan in
one. One patient had received adjuvant chemotherapy and
later chemotherapy for metastatic disease. Thirteen patients
received previous endocrine therapy for advanced disease.
Patient characteristics are listed in Table I.
Response
All 52 patients entered into the study were eligible and
evaluable for response and toxicity assessment. Response
Table I Patient characteristics
Locally
Characteristic Metastatic advanced
No. of patients 36 16
Age (years)
Median 46.5 49.5
Range 33-62 33-62
Performance status
0 13 11
1 13 4
2 7 1
3 3 0
Menstrual status
Pre 18 8
Peri 3 3
Post 15 5
Previous chemotherapy 14 -
Adjuvant (primary medical therapy) 11 (2) -
Metastatica 4 -
Previous endocrine therapy for
advanced disease 13 -
Sites of disease
Local
Breast chest wall 14 16
Regional nodes 13 14
Skin/soft tissue/distant nodes 16
Lung 13
Liver 14
Bone 11
CNS 2
Other 8
No. of disease sites
Median 3
Range (1-5)
aOne patient received adjuvant chemotherapy and chemotherapy
for metastatic disease.
rates are listed in Table II. The overall response rate
(complete plus partial) was 81% (42 of 52 patients) (95%
CI 67-90%).
For metastatic disease, responses were seen in 29 of 36
(81%) patients (95% CI 64-92%), with complete responses
in six (17%) patients (95% CI 6-33%). The response rate in
the 14 patients who had received previous treatment with
chemotherapy was 71% (10/14) (95% CI 42-92%). In the 22
patients who had not received previous chemotherapy, the
response rate was 86% (19/22) (95% CI 65-97%). With the
exception of central nervous system and pleural disease,
responses were observed at all other disease sites (Table III).
Three (8%) patients progressed on ECarboF.
For locally advanced disease, 13 of 16 (81%) patients
responded (95% CI 54-96%), with a complete clinical
response in nine (56%) patients (95% CI 30-80%). Three
patients with locally advanced disease had no change on
treatment.
The median time to response was 55 days (range 27-84
days) for patients with metastatic disease and 32.5 days
(range 22-114 days) for patients with locally advanced
disease.
Patients have been monitored for a median of 11 months
(range 6-31 months). Duration of response and overall
survival are shown in Figures 1 and 2 respectively. The
median response duration for patients with metastatic disease
is 8 months. Only two of the patients with locally advanced
disease have relapsed so far. The median survival duration
for patients with metastatic disease is 14 months, but the
median survival has not yet been reached for patients with
locally advanced disease.
Haematological toxicity
Details of worst haematological toxicity for any course are
listed in Table IV. Severe anaemia requiring transfusion
(haemoglobin level <8.0 g/dl-') occurred in seven patients
(13%); severe thrombocytopenia (platelet count <50 x 109
I`) occurred in five patients (10%), four of whom had
metastatic disease. The principal haematological toxicity was
leucopenia with a WBC <2.0 x 109 l- in 10 of 52 patients
(19%) overall. White cell toxicity was significantly worse in
Table II Response to ECarboF
Metastatic Locally advanced
No. (%) No. (%)
No. of patients 36 16
CR 6 (17) 9 (56)
PR 23 (64) 4 (25)
Overall response 29 (81) 13 (81)
95% CI (64-92) (54-96)
PD 3 (8) 0 (-)
CR, complete remission; PR, partial remission; CI, confidence
interval; PD, progressive disease.
Table HI Response to ECarboF by site (metastatic)
Response
No. of Overall CR
Site patients No. (%) No. (%)
Local/chest wall 14 11 (78) 6 (43)
Regional nodes 13 8 (61) 6 (46)
Soft tissue/skin/
distant nodes 16 14 (87) 8 (50)
Lung 13 10 (77) 4 (31)
Liver 14 8 (57) 3 (21)
Bonea 11 1 (9) 0 (-)
CNS 2 0 (-) 0 ()
Pleural" 8 0 (-) 0 (-)
aEight were not assessable. bSeven patients presented with pleural
effusion and were not assessable.
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patients with metastatic disease (P<0.05, Mann-Whitney
test for trend). One patient continues to have thrombocyto-
penia between 40 and 50 x 109 1 '2 years after completion of
chemotherapy. Bone marrow aspirate, karyotype and
trephine biopsy show no evidence of a myelodysplastic
syndrome.
Non-haematological toxicity
Details of non-haematological toxicity are listed in Table V
and are expressed as the worst toxicity experienced for any
course. With the use of ondansetron and dexamethasone,
only one patient (2%) had significant emesis. Sixteen patients
(31%) had alopecia that required them to wear a wig. The
main side-effect related to the 5-FU was plantar-palmar
erythema, which occurred in five patients (10%); stomatitis
occurred in four patients only (8%) and diarrhoea in none.
Three patients developed severe somnolence (grade 3
lethargy).
There were no complications related to the Hickman line
insertion. Two patients (4%) developed Hickman line
thrombosis, one after the first course and one after the
third course. The line was removed, the patients received full
anticoagulant treatment with warfarin and were continued on
a 5-FU, epirubicin, cyclophosphamide chemotherapy regimen
(FEC). Nine patients (17%) developed infection at the site of
Hickman line insertion that required intravenous antibiotics;
removal was undertaken in three cases. Prophylactic
antibiotics were not prescribed, but line exit sites were
carefully monitored throughout treatment and flucloxacillin
prescribed at the slightest clinical suggestion of infection. In
one patient the Hickman line fractured after the sixth cycle
and had to be removed in a cardiac catheter laboratory.
Dose modifications and treatment delay
Duration of treatment In three patients with locally
advanced disease chemotherapy was stopped early; the
reason for stopping was progression in two (after initial no
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change) and toxicity in one (plantar -palmar erythema grade
3). Eight patients with metastatic disease stopped treatment
early because of progressive disease in six (in three after
initial response) and because of a Hickman line thrombosis in
two.
Dose reductions and delays Treatment was delayed for 1
week in 13 patients (25%), 2 weeks in four patients (8%) and
more than 2 weeks in one patient (2%). Eighteen patients
(35%) had a dose reduction of 5-FU: nine by 25%, four by
24-50%, and five by more than 50%. Eight patients (15%)
had a dose reduction in epirubicin: five by 25%, two by 25-
50% and one by more than 50%. Ten patients (19%) had a
dose reduction in carboplatin: five by 25%, three by 25-50%
and two by more than 50%.
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Table V Non-haematological toxicity
and locally advanced disease: worst
treatment
2 1
Time since start of treatment (years)
Figure 1 Duration of response to ECarboF. , Locally
advanced disease; - - - -, metastatic disease.
WHO grade
1-2 3-4
Parameter No. (%) No. (%)
Emesis 33 (63) 1 (2)
Alopecia 33 (63) 16 (31)
Neuropathy 19 (36) 0 (-)
Stomatitis 23 (43) 4 (8)
Constipation 20 (38) 0 (-)
Diarrhoea 16 (31) 0 (-)
Lethargy 33 (63) 3 (6)
Plantar-palmar syndrome 28 (54) 5 (10)
Rash (other than plantar-palmar) 5 (10) 0 (-)
Hickman line infection 14 (27) 9 (17)
Hickman line thrombosis 0 (-) 2 (4)
Infection 19 (36) 6 (11)
Table IV Haematological toxicity: worst score for any course of treatment
Metastatic WHO grade Locally advanced WHO grade
1-2 3-4 1-2 3-4
Parameter No. (%) No. (%) No. (%) No. (%)
Haemoglobin level 25 (69) 4 (11) 6 (37) 3 (19)
WBC count 22 (61) 8 (22) 6 (37) 2 (12)
Platelet count 5 (14) 4 (11) 2 (12) 1 (6)
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Discussion
We have already shown that a combination of infusional 5-
FU with epirubicin and cisplatin (so-called infusional ECF) is
a highly active regimen in the treatment of locally advanced
and metastatic breast cancer (Jones et al., 1994). We have
subsequently shown the same regimen to be very active as
primary/neoadjuvant chemotherapy against large breast
primaries with an overall response rate of 98% and,
strikingly, a 66% complete remission rate (Smith et al.,
1995). The disadvantage ofthis schedule is the cisplatin. Even
at the moderate dosage we use of 50 mg m-2, the treatment
was associated with severe grade 3/4 nausea and vomiting in
respectively 28% and 20% of patients (Jones et al., 1994;
Smith et al., 1995); in addition, the treatment requires
prolonged 8-12 h intravenous hydration and therefore
necessitated either an overnight inpatient stay or a prolonged
day patient admission.
Carboplatin is an attractive substitute for cisplatin in
terms of reducing the incidence of severe nausea and
vomiting and of neuropathy (Calvert et al., 1982). In
addition, the treatment can be given in an outpatient setting
in a 1 h infusion. There are two potential concerns, however,
with the substitution of carboplatin for cisplatin. Firstly,
delayed myelosuppression necessitates that carboplatin is
usually given on a 4 weekly rather than 3 weekly basis;
epirubicin has therefore also to be given 4 weekly rather than
3 weekly, and the dose intensity of the two-drug combination
is reduced compared with cisplatin/epirubicin. Secondly, there
is the suggestion from non-randomised phase II studies that
the cumulative response rate to carboplatin in previously
untreated patients may be lower than for cisplatin, 31% (27
out of 85 patients) compared with 50% (33 out of 66
patients) (O'Brien et al., 1993).
Despite these theoretical reservations, this phase II study
suggests that infusional ECarboF is as active as ECF and
causes less serious toxicity. Comparative response rates for
ECarboF vs ECF (Jones et al., 1994) in patients with
metastatic breast cancer are 81% vs 83% (complete response
rate 17% vs 24%) and with locally advanced disease 81% vs
86% (complete response rate 56% vs 36%). For metastatic
disease comparative median response duration data were 8 vs
9 months and median survival was 14 months with both
schedules. For locally advanced disease median survival has
not yet been reached in either study. Toxicity was reduced
with ECarboF compared with ECF, including grade 3/4
emesis (2% vs 28%) and neuropathy (0% vs 2%). It was also
of interest that we observed less plantar-palmar erythema
(10% vs 26%) and less alopecia requiring a wig (31% vs
56%). Moreover, replacing cisplatin with carboplatin was not
associated with a significant increase in severe anaemia (13%
vs 5% with ECF) or grade 3-4 leucopenia (19% vs 28%);
severe thrombocytopenia, however, occurred in 10% vs 0%
(Jones et al., 1994). Finally ECarboF, as anticipated, could
be delivered as outpatient therapy. These comparative data
are of course sequential rather than randomised; nevertheless,
the criteria for entry were identical, and they suggest that
infusional ECarboF has very similar activity to infusional
ECF but with less toxicity. Furthermore, cyclophosphamide
is a much used drug in breast cancer, with a similar single-
agent response rate to carboplatin or cisplatin, and much
cheaper. Cyclophosphamide is, therefore, another appropriate
candidate to replace cisplatin in the infusional ECF schedule,
and we are currently addressing this issue in a randomised
phase II trial in patients with metastatic disease.
Both these infusional schedules are highly active against
advanced/metastatic breast cancer, with overall response rates
higher than those usually reported with conventional che-
motherapy regimens (Tormey et al., 1982; Cummings et al.,
1985; Falksonetal., 1985;Aisneretal., 1987; Coatesetal., 1987;
Jodrell et al., 1991; Powles et al., 1991), albeit in selected
patients. Both, however, are also associated with a high relapse
rate in patients with metastatic disease, suggesting that their
main role may prove to be in the management ofpatients with
high risk early breast cancer (neoadjuvant or adjuvant
chemotherapy) or with locally advanced or inflammatory
disease. Infusional ECarboF offers a useful step forward
compared with ECF in terms of decreased toxicity and the
opportunity for outpatient-based chemotherapy. Cost is an
obvious but complex factor here: carboplatin is more expensive
than cisplatin, but this is balanced by the potential savings of
outpatienttherapy. Theseschedulesnowmeritcomparisonwith
conventional chemotherapy in randomised trials and we are
currently proceeding with two such trials, first as primary/
neoadjuvant chemotherapy for large early breast cancer and
second as adjuvant chemotherapy in younger women with
involved axillary nodes.
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